The emerging role of tranexamic acid and its principal target,plasminogen,in skeletal health  

作　　者：Weixin Xie Antonia Donat Shan Jiang Anke Baranowsky Johannes Keller 

机构地区：[1]Department of Trauma and Orthopedic Surgery,University Medical Center Hamburg-Eppendorf,Hamburg 20246,Germany

出　　处：《Acta Pharmaceutica Sinica B》2024年第7期2869-2884,共16页药学学报（英文版）

基　　金：supported by the German Research Foundation(KE 2179/9-1,Germany).

摘　　要：The worldwide burden of skeletal diseases such as osteoporosis,degenerative joint disease and impaired fracture healing is steadily increasing.Tranexamic acid(TXA),a plasminogen inhibitor and anti-fibrinolytic agent,is used to reduce bleeding with high effectiveness and safety in major surgical procedures.With its widespread clinical application,the effects of TXA beyond anti-fibrinolysis have been noticed and prompted renewed interest in its use.Some clinical trials have characterized the effects of TXA on reducing postoperative infection rates and regulating immune responses in patients undergoing surgery.Also,several animal studies suggest potential therapeutic effects of TXA on skeletal diseases such as osteoporosis and fracture healing.Although a direct effect of TXA on the differentiation and function of bone cells in vitro was shown,few mechanisms of action have been reported.Here,we summarize recent findings of the effects of TXA on skeletal diseases and discuss the underlying plasminogen-dependent and-independent mechanisms related to bone metabolism and the immune response.We furthermore discuss potential novel indications for TXA application as a treatment strategy for skeletal diseases.

关 键 词：Tranexamic acid OSTEOPOROSIS OSTEOARTHRITIS Fracture healing Bone metabolism INFLAMMATION PLASMINOGEN FIBRINOLYSIS 

分 类 号：R68[医药卫生—骨科学]